NS
Noa Sher
Chief Scientist at Minovia Therapeutics
View Noa's Contact Info for Free. Sign Up and Get 50 Free Contacts Per Month.Get Started for Free
Work Experience
Chief Scientist
2018 - Present · 6 years and 11 months
Product Profile Research Manager
2015 - 2018 · 3 years
Bioinformatics Service Unit of University of Haifa
Head
2013 - 2015 · 2 years
Company Details
11-50 Employees
Minovia is a clinical stage company focused on the development and application of mitochondrial cell therapies for patients suffering mitochondrial dysfunction. Mitochondrial Augmentation Technology (MAT) is a cell therapy platform where an off-the-shelf allogeneic isolated mitochondria are developed as cryopreserved, healthy and functional, energy producing organelles and used to augment various cell types to be used as therapeutics products. The lead product, MNV-201 consists of autologous hematopoietic stem and progenitor cells (HSPCs) augmented ex vivo with healthy mitochondria. MNV-201 is currently in clinical trial for Pearson Syndrome and in Pre-clinical stage for Myelodysplastic Syndrome (MDS) indicating encouraging clinical and pre-clinical proof-of-concept for both primary mitochondrial diseases and age-related bone marrow failures. In Minovia we developed novel mitochondria-based biomarkers that allows us to stratify patients according to their "MitoScore". Minovia is establishing a novel aspect of cell therapy quality focusing on mitochondrial science, developing robust analytical methods to measure cellular mitochondrial function, as well as modalities to rescue mitochondrial dysfunction in different cell therapies.
Year Founded
2012
Social Media
Linkedin
Industry
Biotechnology Research
HQ Location
Haifa, Israel 3902603, IL
Keywords
Biotechnologycell therapyRare diseasesMitochondriMitochondrial DiseasesMitochondrial AugmentatioMitochondrial dysfunctio
Discover More About Cleveland Clinic

Find verified contacts of Noa Sher in seconds from 700M people profiles. Start now!

No Credit Card Needed. By signing up, you understand and agree to Futern's Terms and Policy.